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The ability to detect disease early or tailor personalized patient treatments depends on the 
identification and validation of novel biomarkers. Large systems biology studies have identified 
genetic biomarkers, such as DNA mutations, that are now used in the clinic to influence patient care. 
Protein levels are also used for diagnostics, but assays to reliably and reproducibly measure protein 
abundance exist for only 5% of the proteins encoded by the human genome. This deficit hinders the 
ability of researchers to look globally at the proteome for novel protein biomarkers of disease. A new 
study published in Nature Methods, by a team of international collaborators led by Dr. Amanda 
Paulovich from the Clinical Research Division, demonstrates the feasibility of large-scale efforts to 
standardize protein measurements. "We imagine a day when any human protein of interest can be 
reliably quantified (and thus effectively studied) by any researcher in the world," says Dr. Paulovich.  
 Researchers from the Paulovich Laboratory, the Broad Institute in Cambridge, Mass., and the Seoul 
National University and Korea Institute of Science and Technology, South Korea modeled what a 
global assay development effort might look like. They used a sensitive method called multiple 
reaction monitoring mass spectrometry (MRM-MS) to measure protein levels. MRM-MS is a targeted 
approach to measuring proteins using specialized instruments that can be "tuned" to look for small 
protein fragments of interest in biological specimens. Proteins are digested with a protease, such as 
trypsin, to generate smaller peptide fragments. One or more unique peptides are identified for each 
protein, and used as a surrogate to quantify that protein’s abundance. This method increases 
sensitivity and reproducibility compared to traditional MS approaches by filtering out the noise. 
In this pilot study, the researchers configured and validated across three laboratories 645 novel 
MRM assays representing 319 proteins (equivalent to 1.5% of the human proteome). These proteins 
were chosen because they are differentially expressed across 30 different human breast cancer cell 
lines. The MRM assays were multiplexed in four groups (ranging from 156-169 peptides) with 
median assay precision of 5.4%, and successful reproduction of assay results across the three 
laboratories (0.96 ≤ R2  ≤ 0.99). Importantly, the researchers demonstrated that MRM-based peptide 
measurements in individual breast cancer cell lines were able to discriminate between molecular  
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subtypes of breast cancer, including HER2, estrogen receptor (ER), and basal-luminal status. 
Kennedy et al. then compared mRNA expression levels to protein levels in the different breast 
cancer cell lines, confirming genome-driven changes were altered in the measured proteomes for 
specific cells. Importantly, the researchers found novel changes in protein levels that were not found 
when looking at mRNA expression levels, which could identify potential disease genes specific to the 
different breast cancer subtypes. Taken together, these results demonstrate the potential of 
developing MRM assays to measure the entire proteome in search for novel biomarkers. 
While the current study used cell lysates, the MRM assay platform can be applied to protein extracts 
from any type of biospecimen, including human tissues. Previously, Dr. Paulovich and collaborators 
used MRM-MS to measure human proteins in plasma (Whiteaker et al., 2011). However, the limited 
yield of protein from a biopsy or surgical specimen and the presence of multiple cell types 
encountered in tumor tissue samples are two hurdles that need to be overcome for clinical 
applicability of the approach. According to Dr. Paulovich, "Broadly available, standardized tools for 
quantifying human proteins would fundamentally transform biomedical research and lead to 
improvements in patient diagnosis and treatment by facilitating precision medicine. This will enable 
the translation of basic research into tangible medical benefit to patients and society." 
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Image provided by Dr. Amanda Paulovich 
A one hour targeted mass spectrometry run allows for quantification of 150 peptides from 75 
proteins expressed in breast cancer cell lines (inset). 
 
